The inflammatory lung microenvironment; a key mediator in msc licensing
Dunbar, Hazel ; Weiss, Daniel J. ; Enes, Sara Rolandsson LU
; Laffey, John G.
and English, Karen
(2021)
In Cells
10(11).
- Abstract
Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better under-stand how the disease microenvironment influences MSC activation and... (More)
Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better under-stand how the disease microenvironment influences MSC activation and therapeutic actions, in addition to the need for a patient-stratification approach.
(Less)
- author
- Dunbar, Hazel
; Weiss, Daniel J.
; Enes, Sara Rolandsson
LU
; Laffey, John G.
and English, Karen
- organization
- publishing date
- 2021-11
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cytokines, Immunomodulatory, Inflammatory, Licensing, Lung, Microenvironment, MSC
- in
- Cells
- volume
- 10
- issue
- 11
- article number
- 2982
- publisher
- MDPI AG
- external identifiers
-
- scopus:85118272707
- pmid:34831203
- ISSN
- 2073-4409
- DOI
- 10.3390/cells10112982
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- id
- 9236a25d-f104-40b5-9136-b15a5d802275
- date added to LUP
- 2021-11-22 13:07:51
- date last changed
- 2024-06-15 21:10:40
@article{9236a25d-f104-40b5-9136-b15a5d802275,
abstract = {{<p>Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better under-stand how the disease microenvironment influences MSC activation and therapeutic actions, in addition to the need for a patient-stratification approach.</p>}},
author = {{Dunbar, Hazel and Weiss, Daniel J. and Enes, Sara Rolandsson and Laffey, John G. and English, Karen}},
issn = {{2073-4409}},
keywords = {{Cytokines; Immunomodulatory; Inflammatory; Licensing; Lung; Microenvironment; MSC}},
language = {{eng}},
number = {{11}},
publisher = {{MDPI AG}},
series = {{Cells}},
title = {{The inflammatory lung microenvironment; a key mediator in msc licensing}},
url = {{http://dx.doi.org/10.3390/cells10112982}},
doi = {{10.3390/cells10112982}},
volume = {{10}},
year = {{2021}},
}